Latest News
News Functions
Additional Functions
9 July 2015
Karolinska Development AB
Karolinska Development divests its holding in Pharmanest to an investment consortium comprising Östersjöstiftelsen, Recipharm Venture Fund and Praktikerinvest
Karolinska Development AB
Karolinska Development implements a more prudent and representative approach to reporting the fair value of its portfolio – divestment of Pharmanest
21 May 2015
Karolinska Development AB
Karolinska Development´s Annual General Meeting 2015
6 May 2015
Karolinska Development AB
Karolinska Development AB (publ) – Interim Report January – March 2015
4 May 2015
Karolinska Development AB
Karolinska Development – Interim Report January – March, invitation to conference call and webcast
28 April 2015
Karolinska Development AB
Karolinska Development’s Annual Report 2014 has been published
Karolinska Development AB
Karolinska Development announces preliminary portfolio valuation for the January-March 2015 Interim Report
20 April 2015
Karolinska Development AB
Aprea presents preliminary clinical Phase Ib/II results in ovarian cancer at AACR with APR-246 – a novel candidate drug that restores mutant p53 protein into its wild-type function
14 April 2015
Karolinska Development AB
Notice of Annual General Meeting in Karolinska Development AB (publ)
27 March 2015
Karolinska Development AB
Clanotech granted Orphan Drug Designation by the U.S. FDA
Karolinska Development AB
Karolinska Development sells its stake in Axelar to Östersjöstiftelsen
20 March 2015
Karolinska Development AB
Dilaforette receives Orphan Drug Designation in the U.S. for sevuparin in Sickle-Cell Disease
3 March 2015
Karolinska Development AB
Jim Van heusden appointed CEO of Karolinska Development
2 March 2015
Karolinska Development AB
Karolinska Development confirms full payment in the rights issue of convertibles
19 February 2015
Karolinska Development AB
Dilaforette Announces Co-Development Agreement with Ergomed for Sickle-Cell Disease Treatment
18 February 2015
Karolinska Development AB
Karolinska Development AB (publ) – Year-End Report 2014
28 January 2015
Karolinska Development AB
CEO Bruno Lucidi leaves Karolinska Development and Deputy CEO Terje Kalland is appointed Acting CEO
16 January 2015
Karolinska Development AB
Update of Karolinska Development rights issue outcome
30 December 2014
Karolinska Development AB
Karolinska Development announces outcome of the rights issue of convertibles
Karolinska Development AB
Change of number of shares and votes in Karolinska Development
8 December 2014
Karolinska Development AB
Purchase of own shares to cover social security fees related to incentive program
4 December 2014
Karolinska Development AB
Karolinska Development’s Extraordinary General Meeting
12 November 2014
Karolinska Development AB
The option rights with Athera will not be exercised due to re-evaluation of Boehringer Ingelheim’s R&D strategy – clinical development of Athera’s antibody proceeds as planned
Karolinska Development AB
Extraordinary General Meeting in Karolinska Development AB (publ)
5 November 2014
Karolinska Development AB
Karolinska Development secures funding from CP Group, a leading Asian life science investor, and initiates preparation for a convertible bond issue
21 October 2014
Karolinska Development AB
Karolinska Development AB (publ) – Interim Report January – September 2014
Karolinska Development AB
Athera initiates Phase I trial with its fully human antibody PC-mAb
20 October 2014
Karolinska Development AB
Clanotech receives orphan drug designation in the EU
Karolinska Development AB
OssDsign’s Cranioplug receives marketing approval in the US
Karolinska Development AB
Forendo Pharma announces the US licensing of fispemifene to Apricus Biosciences targeting urological conditions in men